文献速递胸部肿瘤

TLR9激动剂lefitolimod用于广泛期小细胞肺癌维持治疗的II期研究

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study.
PubMed 文献 · Ann Oncol · 2018-01-01

IMPULSE II期研究将103例一线化疗后客观缓解的广泛期小细胞肺癌患者按3:2随机分配至lefitolimod维持治疗组或局部标准治疗组。结果显示意向治疗人群无进展生存和总生存无显著获益,但安全性良好,且在活化CD86+ B细胞低频率和合并COPD的两个预设亚组中观察到总生存获益信号。

要点

  • lefitolimod维持治疗在ES-SCLC意向治疗人群未改善PFS和OS。
  • 安全性良好,药效学证实单核细胞活化和IP-10产生。
  • 活化CD86+ B细胞低频率和COPD亚组显示OS获益趋势。

核心结论

  • lefitolimod在ES-SCLC意向治疗人群未显著改善总生存,但安全性良好且在两个预设亚组中显示OS获益信号。

研究设计与样本

  • 探索性、对照、随机、国际II期IMPULSE研究,纳入103例一线含铂化疗四周期后客观缓解的ES-SCLC患者,按3:2随机接受lefitolimod维持治疗或局部标准治疗。

主要发现

  • 意向治疗人群未观察到lefitolimod对无进展生存和总生存的相关影响。
  • 药效学评估显示lefitolimod激活单核细胞并诱导IP-10产生。
  • 活化CD86+ B细胞低频率患者(n=38/88)中lefitolimod组OS的HR为0.53(95%CI: 0.26-1.08)。
  • 合并COPD患者(n=25/103)中lefitolimod组OS的HR为0.48(95%CI: 0.20-1.17)。

临床怎么用

  • lefitolimod目前不推荐用于ES-SCLC常规维持治疗,需进一步研究验证亚组获益。

局限性

  • 探索性II期研究样本量有限,亚组分析为预设但非主要终点,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The immune surveillance reactivator lefitolimod (MGN1703), a DNA-based TLR9 agonist, might foster innate and adaptive immune response and thus improve immune-mediated control of residual cancer disease. The IMPULSE phase II study evaluated the efficacy and safety of lefitolimod as maintenance treatment in extensive-stage small-cell lung cancer (ES-SCLC) after objective response to first-line chemotherapy, an indication with a high unmet medical need and stagnant treatment improvement in the last decades. PATIENTS AND METHODS: 103 patients with ES-SCLC and objective tumor response (as per RECIST 1.1) following four cycles of platinum-based first-line induction therapy were randomized to receive either lefitolimod maintenance therapy or local standard of care at a ratio of 3 : 2 until progression or unacceptable toxicity. RESULTS: From 103 patients enrolled, 62 were randomized to lefitolimod, 41 to the control arm. Patient demographics and response patterns to first-line therapy were balanced. Lefitolimod exhibited a favorable safety profile and pharmacodynamic assessment confirmed the mode-of-action showing a clear activation of monocytes and production of interferon-gamma-induced protein 10 (IP-10). While in the intent-to-treat (ITT) population no relevant effect of lefitolimod on progression-free and overall survival (OS) could be observed, two predefined patient subgroups indicated promising results, favoring lefitolimod with respect to OS: in patients with a low frequency of activated CD86+ B cells (hazard ratio, HR 0.53, 95% CI: 0.26-1.08; n = 38 of 88 analyzed) and in patients with reported chronic obstructive pulmonary disease (COPD) (HR 0.48, 95% CI: 0.20-1.17, n = 25 of 103). CONCLUSIONS: The IMPULSE study showed no relevant effect of lefitolimod on the main efficacy end point OS in the ITT, but (1) the expected pharmacodynamic response to lefitolimod, (2) positive OS efficacy signals in two predefined subgroups and (3) a favorable safety profile. These data support further exploration of lefitolimod in SCLC.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Thomas M, Ponce-Aix S, Navarro A, et al. Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study. Ann Oncol. 2018. PMID: 30137193. doi:10.1093/annonc/mdy326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。